25/10/2014 05:27:18 Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
08/13/20149:47AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Macy's Inc. (M), Deere & Co. (DE) and Seaworld Entertainment Inc. (SEAS). Macy's reported disappointing second-quarter results and reduced its sales outlook for the year, adding more concern to an already struggling retail sector... More...>>
07/30/201412:00PMGLOBEMyriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014
SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014. The Company also... More...>>
06/10/20144:05PMGLOBECrescendo Bioscience to Present Multiple Studies at 2014 EULAR Meeting
Vectra® DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European... More...>>
06/09/20144:05PMGLOBEMyriad Announces Retirement of James Evans, Chief Financial Officer
SALT LAKE CITY, June 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until... More...>>
06/03/20147:05AMGLOBEMyriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35th annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes... More...>>
06/02/201410:45AMGLOBEMyriad Genetics Announces Participation in Innovative Collaboration to Accelerate Hereditary Cancer Research
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically... More...>>
06/02/20147:05AMGLOBEMyriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented several clinical studies on the Myriad myRisk™ Hereditary Cancer test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Among the important new findings is that the myRisk... More...>>
06/02/20147:05AMGLOBEMyriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical validation study of the Myriad myPath™ Melanoma test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The Myriad myPath Melanoma test is a novel... More...>>
05/30/20147:05AMGLOBEMyriad Presents Data on BRACAnalysis CDx(TM) and HRD(TM) at 2014 ASCO Meeting
SALT LAKE CITY, May 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its BRACAnalysis CDx™ and HRD™... More...>>
05/20/20147:05AMGLOBEProlaris(R) Test Predicts Mortality Risk in Prostate Cancer Biopsy Study
SALT LAKE CITY, May 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla.  The study is the largest validation study to date of any gene-based prognostic... More...>>
05/15/20147:05AMGLOBEMyriad Strengthens Commitment to Cancer Research at the ASCO 50th Annual Meeting
SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from 11 clinical studies with its molecular diagnostic tests will be featured at the 2014 American Society of Clinical Oncology annual meeting to be held May 30-June 3, 2014 in Chicago, Ill. Abstracts of the... More...>>
05/14/20149:46AMZACKSOragenics (OGEN) Catches Eye: Stock Rises 9.7% - Tale of the Tape
Oragenics Inc. (OGEN) was a big mover last session with its shares rising nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost nearly 25% in the past one-month time frame. This biotechnology... More...>>
05/14/20147:05AMGLOBECrescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis
SALT LAKE CITY, May 14, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Crescendo's Vectra DA blood test. The study is a retrospective analysis of data... More...>>
05/09/20147:05AMGLOBEMyriad Genetics to Present at the Bank of America 2014 Healthcare Conference
SALT LAKE CITY, May 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference, at 10:00 a.m. Pacific on May 13, 2014, at the Encore at the Wynn in Las Vegas... More...>>
05/08/20143:00PMZACKSMyriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog
Myriad Genetics (MYGN) reported earnings per share (EPS) of 60 cents in the third quarter of fiscal 2014, registering a remarkable 30.4% beat over the Zacks Consensus Estimate as well as the year-over-year adjusted number. EPS growth was boosted by a strong top line and a reduced share count. Without these adjustments... More...>>
05/06/20144:05PMGLOBEMyriad Genetics Reports Financial Results for Third Quarter of Fiscal Year 2014
SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for the fiscal third quarter and nine months ended March 31, 2014, increased its fiscal year 2014 guidance, and provided an update on recent business highlights. Revenue for the third quarter was $182.9... More...>>
05/06/20147:05AMGLOBEMyriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members
SALT LAKE CITY, May 6, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and the myRisk Hereditary Cancer test for patients who meet the hereditary cancer testing... More...>>
05/05/20149:50AMZACKSGeron Reports In-Line Q1 Loss - Analyst Blog
Shares of Geron Corporation (GERN) were down 6.09% after the company reported first quarter 2014 results. Geron posted a net loss of 6 cents per share in the first quarter of 2014, in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 9 cents. First quarter revenues of $474,000 were below the... More...>>
05/05/20148:59AMZACKSIs A Short Squeeze Ahead for Myriad Genetics (MYGN)? - Tale of the Tape
Many investors appear to be quite bearish on Myriad Genetics, Inc. (MYGN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 52.1% of the float is sold short, suggesting an extreme level of bearishness for MYGN. However, it is worth noting that earnings estimates have actually... More...>>
05/01/20147:05AMGLOBEMyriad Genetics to Present Three Clinical Studies on Prolaris(R) at the 2014 American Urological Association Annual Meeting
SALT LAKE CITY, May 1, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced clinical data from three studies on Prolaris in prostate cancer patients will be featured at the 2014 American Urological Association (AUA) Annual Meeting, being held May 16–21, 2014, in Orlando, Fla. Prolaris is... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mygn141025 05:27